[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623188":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":45,"locations":51,"responsibleParty":65,"collaborators":32,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":32,"enrollmentInfo":78,"targetDuration":32,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":91,"whyStopped":32,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"0.25% Bupivacaine Intrapleural Analgesia","EXPERIMENTAL","Participants receive programmed intermittent intrapleural administration of 0.25% bupivacaine via a chest drainage tube connected to a programmed infusion pump for postoperative analgesia following video-assisted thoracoscopic surgery. All participants also receive standard multimodal analgesia, including intravenous patient-controlled analgesia, regional nerve block, and rescue analgesic medications as clinically indicated.",[13,14],"Drug: Bupivacaine 0.25%","Other: Multimodal Analgesia",{"label":16,"type":10,"description":17,"interventionNames":18},"0.125% Bupivacaine Intrapleural Analgesia","Participants receive programmed intermittent intrapleural administration of 0.125% bupivacaine via a chest drainage tube connected to a programmed infusion pump for postoperative analgesia following video-assisted thoracoscopic surgery. All participants also receive standard multimodal analgesia, including intravenous patient-controlled analgesia, regional nerve block, and rescue analgesic medications as clinically indicated.",[19,14],"Drug: Bupivacaine 0.125%",{"label":21,"type":22,"description":23,"interventionNames":24},"Placebo Intrapleural Analgesia (Normal Saline)","PLACEBO_COMPARATOR","Participants receive programmed intermittent intrapleural administration of normal saline via a chest drainage tube connected to a programmed infusion pump as a placebo control for postoperative analgesia following video-assisted thoracoscopic surgery. All participants also receive standard multimodal analgesia, including intravenous patient-controlled analgesia, regional nerve block, and rescue analgesic medications as clinically indicated.",[25,14],"Drug: Normal Saline",[27,33,37,41],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Bupivacaine 0.125%","Bupivacaine 0.125% is administered intrapleurally via a chest drainage tube connected to a programmed infusion pump, using a programmed intermittent dosing regimen for postoperative analgesia following video-assisted thoracoscopic surgery.",[16],null,{"type":28,"name":34,"description":35,"armGroupLabels":36,"otherNames":32},"Bupivacaine 0.25%","Bupivacaine 0.25% is administered intrapleurally via a chest drainage tube connected to a programmed infusion pump, using a programmed intermittent dosing regimen for postoperative analgesia following video-assisted thoracoscopic surgery.",[9],{"type":28,"name":38,"description":39,"armGroupLabels":40,"otherNames":32},"Normal Saline","Normal saline is administered intrapleurally via a chest drainage tube connected to a programmed infusion pump, using a programmed intermittent dosing regimen as a placebo control for postoperative analgesia following video-assisted thoracoscopic surgery.",[21],{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":32},"Multimodal Analgesia","All participants receive standard multimodal analgesia, including intravenous patient-controlled analgesia, regional nerve block, and rescue analgesic medications as clinically indicated, in addition to the assigned intrapleural intervention.",[16,9,21],[46],{"name":47,"role":48,"phone":49,"phoneExt":32,"email":50},"Leo Li","CONTACT","021-18621710790","18621710790@163.com",[52],{"facility":53,"status":32,"city":54,"state":32,"zip":32,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Shanghai Pulmonary Hospital","Shanghai","China","CN",{"type":58,"coordinates":59},"Point",[60,61],121.45806,31.22222,{"lat":61,"lon":60},[64],{"name":47,"role":48,"phone":49,"phoneExt":32,"email":50},{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Wei Wu","Attending Physician, Department of Anesthesiology","100623188","phase-4-intrapleural-bupivacaine-analgesia-for-postoperative-pain-management-after-minimally-invasive-video-assisted-thoracoscopic-surgery-a-randomized-controlled-trial-100623188",false,"NCT07393386","Intrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial","IBVATS","Inclusion Criteria:\n\n1. Patients scheduled for elective video-assisted thoracoscopic surgery\n2. Age≥18 years\n3. American Society of Anesthesiologists (ASA) physical status classification I-III\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. History of chronic pain\n3. History of alcohol or opioid dependence\n4. Significant cardiopulmonary dysfunction, including heart failure or severe cardiac conduction abnormalities\n5. Coexisting central nervous system disorders\n6. Hepatic or renal dysfunction\n7. Known hypersensitivity to local anesthetics or opioids\n8. Local infection at or near the planned site of regional anesthesia, or systemic infection\n9. Language impairment or difficulty in communication\n10. Refusal to participate in the study or refusal to use patient-controlled analgesia\n11. Concurrent participation in another clinical trial","ALL","18 Years",{"count":79,"type":80},249,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","Postoperative pain is common after video-assisted thoracoscopic surgery (VATS), with pleural irritation caused by chest tube placement being a major contributor. Inadequate pain control may impair respiratory function, delay postoperative recovery, and increase the risk of complications. However, effective and targeted analgesic strategies specifically addressing chest tube-related pain remain limited.\n\nThis is a single-center, prospective, randomized, double-blind, placebo-controlled superiority trial designed to evaluate the efficacy and safety of programmed intermittent intrapleural administration of bupivacaine at different concentrations for postoperative analgesia after VATS. A total of 249 patients undergoing VATS will be randomly assigned in a 1:1:1 ratio to receive intrapleural injections of 0.25% bupivacaine, 0.125% bupivacaine, or normal saline. The primary outcome is pain intensity during coughing within 48 hours after surgery. Secondary outcomes include pain intensity at rest, plasma bupivacaine concentrations, quality of postoperative recovery, cumulative opioid consumption, and postoperative inflammatory marker levels.\n\nThis study aims to provide evidence to inform analgesic strategies for chest tube-related pain following VATS and to clarify the optimal use and safety profile of intrapleural bupivacaine.",[86],"Pain Management",[88,89,90],"Postoperative pain","Thoracoscopic surgery","Intrapleural analgesia","NOT_YET_RECRUITING","2026-02-01",{"date":94,"type":95},"2026-02-06","ACTUAL",{"date":92,"type":80},{"date":98,"type":80},"2028-06-30",{"name":5,"class":6},1]